Skip to main content
. Author manuscript; available in PMC: 2015 Aug 1.
Published in final edited form as: Kidney Int. 2014 Jul 23;87(2):409–416. doi: 10.1038/ki.2014.261

Figure 1. HLA antibody rebound following HLA-incompatible transplantation: decreased incidence and magnitude in recipients receiving rituximab induction.

Figure 1

HLA antibodies (54 DSA and 202 non-DSA) were measured prior to desensitization (time 0) and at four post-transplant time points (1, 3, 6, 12 months) in patients transplanted with or without rituximab induction. MFI values were normalized to the positive control bead and percent change from time zero was plotted. The incidence of post-transplant DSA (p = 0.03) and non-DSA class I and class II HLA antibody (p= 0.0027) rebound and the magnitude of the antibody rebound (p=0.02) were lower in patients transplanted with rituximab induction compared to those without induction.